Andrew  Callos net worth and biography

Andrew Callos Biography and Net Worth

EVP of Cytokinetics

Andrew joined us as Executive Vice President, Chief Commercial Officer in March 2021.

Andrew has a deep biopharma background which includes well over 20 years at Pfizer and Wyeth Pharmaceuticals, including roles of increasing responsibility overseeing US and International pharmaceutical franchises. Most recently Andrew served as Regional President and General Manager North America, Upjohn Business Unit at Pfizer. Prior to this role and during his 11+ years at Pfizer, he held several leadership positions including Vice President U.S. Cardiology & Metabolic Marketing where he led the commercialization of Eliquis in the U.S., Vice President and Head of Inflammation Marketing Europe and Vice President Global Commercial Development Rare Disease. Prior to Pfizer, Andrew spent over 10 years at Wyeth Pharmaceuticals in various roles within Business Planning & Analysis, ultimately serving as AVP Marketing across several products. Andrew started the first 7 years of his career as a Consulting Manager at Accenture.

Andrew received a B.S. in Commerce and Engineering from Drexel University.

Andrew enjoys spending time with wife Alicia and two children, Daniel, and Julia. In addition, he is an avid runner, home chef, bourbon enthusiast (in moderation of course), and sports fan – especially his lifelong love of the Dallas Cowboys!

What is Andrew Callos' net worth?

The estimated net worth of Andrew Callos is at least $1.67 million as of March 14th, 2025. Callos owns 37,663 shares of Cytokinetics stock worth more than $1,670,731 as of March 14th. This net worth approximation does not reflect any other assets that Callos may own. Additionally, Callos receives an annual salary of $752,840.00 as EVP at Cytokinetics. Learn More about Andrew Callos' net worth.

How old is Andrew Callos?

Callos is currently 55 years old. There are 5 older executives and no younger executives at Cytokinetics. The oldest executive at Cytokinetics is Dr. James A. Spudich Ph.D., Co-Founder & Member of Scientific Advisory Board, who is 82 years old. Learn More on Andrew Callos' age.

What is Andrew Callos' salary?

As the EVP of Cytokinetics, Incorporated, Callos earns $752,840.00 per year. There are 2 executives that earn more than Callos. The highest earning executive at Cytokinetics is Mr. Robert I. Blum, President and Chief Executive Officer, who commands a salary of $1,330,000.00 per year. Learn More on Andrew Callos' salary.

How do I contact Andrew Callos?

The corporate mailing address for Callos and other Cytokinetics executives is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. Cytokinetics can also be reached via phone at (650) 624-3000 and via email at investor@cytokinetics.com. Learn More on Andrew Callos' contact information.

Has Andrew Callos been buying or selling shares of Cytokinetics?

During the past quarter, Andrew Callos has sold $149,065.07 of Cytokinetics stock. Most recently, Andrew Callos sold 100 shares of the business's stock in a transaction on Friday, March 14th. The shares were sold at an average price of $45.00, for a transaction totalling $4,500.00. Following the completion of the sale, the executive vice president now directly owns 37,663 shares of the company's stock, valued at $1,694,835. Learn More on Andrew Callos' trading history.

Who are Cytokinetics' active insiders?

Cytokinetics' insider roster includes Muna Bhanji (Director), Robert Blum (President and Chief Executive Officer), Andrew Callos (EVP), Santo Costa (Director), David Cragg (Insider), L. Gage (Director), Robert Harrington (Director), John Henderson (Director), Ching Jaw (CFO), Edward Kaye (Director), Fady Malik (EVP), B. Parshall (Director), Mark Schlossberg (SVP), Sandford Smith (Director), Wendall Wierenga (Director), and Robert Wong (CAO). Learn More on Cytokinetics' active insiders.

Are insiders buying or selling shares of Cytokinetics?

During the last year, insiders at the biopharmaceutical company sold shares 46 times. They sold a total of 344,157 shares worth more than $19,098,882.02. The most recent insider tranaction occured on March, 14th when EVP Andrew Callos sold 100 shares worth more than $4,500.00. Insiders at Cytokinetics own 3.4% of the company. Learn More about insider trades at Cytokinetics.

Information on this page was last updated on 3/14/2025.

Andrew Callos Insider Trading History at Cytokinetics

See Full Table

Andrew Callos Buying and Selling Activity at Cytokinetics

This chart shows Andrew Callos's buying and selling at Cytokinetics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$149ksoldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$100k$0$100kTotal Insider BuyingTotal Insider Selling

Cytokinetics Company Overview

Cytokinetics logo
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $44.36
Low: $43.52
High: $45.00

50 Day Range

MA: $46.34
Low: $41.56
High: $51.12

2 Week Range

Now: $44.36
Low: $40.53
High: $75.71

Volume

1,337,107 shs

Average Volume

1,558,329 shs

Market Capitalization

$5.25 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.95